Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00313833 · ClinicalTrials.gov registry record · Phase 3

Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.

A Phase 3 study, sponsored by Purdue Pharma.

Completed
Registry status
Phase 3
Development phase
100
Enrollment target

NCT00313833: Completed Phase 3 study, sponsored by Purdue Pharma.

NCT00313833 is a Phase 3 study that has completed, run by Purdue Pharma. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00313833, a Phase 3 study, has completed, sponsored by Purdue Pharma.

COMPLETED
Registry status
Phase 3
Development phase
100 participants
Enrollment target

Study Summary

This pilot study was designed to evaluate the effectiveness and tolerability of the buprenorphine transdermal system versus placebo on health outcomes in elderly residents in supervised living environments. The treatment intervention duration is 42 days during which time supplemental analgesic medication (usual analgesic care) will be provided to all subjects in addition to study drug.

Interventions

  • DRUG Buprenorphine transdermal delivery system

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2000-12
Est. Completion 2001-11
Phase Phase 3
Purdue Pharma

54 total trials

What the finished NCT00313833 record still lists

NCT00313833 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 1 intervention - of which Buprenorphine transdermal delivery system is the first listed.

NCT00313833 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00313833 about?

NCT00313833 is a clinical study titled "Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.". This pilot study was designed to evaluate the effectiveness and tolerability of the buprenorphine transdermal system versus placebo on health outcomes in elderly residents in supervised living environments. The treatment intervention duration is 42 days during which time supplemental analgesic medic...

What is the current status of trial NCT00313833?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2000-12. Estimated completion is 2001-11.

What interventions are being tested in trial NCT00313833?

The interventions under investigation include: Buprenorphine transdermal delivery system (DRUG).

Who is sponsoring clinical trial NCT00313833?

This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00313833's enrollment target sits among peer trials

100 1681st of 2000 higher than 288 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00313833, the US trial registry maintained by the National Library of Medicine. NCT00313833 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.